Skip to main content
. 2017 Jun 10;7(6):144. doi: 10.3390/nano7060144

Figure 4.

Figure 4

T2-weighted MR imaging and biocompatibility of CoFe2O4-HPs-FAs. (a) T2-weighted MR images of prostate cancer cells (PC-3 cells) treated with CoFe2O4-HPs-Fas; (b) Plot of T2 relaxation rate r2 (1/T2) for CoFe2O4-HPs-Fas; (c) Cytotoxicity of CoFe2O4-HPs-FAs (60 nm) in fibroblasts (L-929 cells) and prostate cancer cells (PC-3 cells). Data are expressed as the mean ± standard deviation (n = 6).